Deals this week: Horama, Voyager Therapeutics, Fibrocell Science

10th November 2017 (Last Updated November 10th, 2017 00:00)

Horama SAS has raised €19m ($22m) in a series B funding round led by Fundplus, Pontifax Ltd, and IDInvest Partners. 

Horama SAS has raised €19m ($22m) in a series B funding round led by Fundplus, Pontifax Ltd, and IDInvest Partners.

The French clinical-stage biotechnology company plans to use the funds towards the development of gene therapy treatments for rare retinal diseases.

US-based biotechnology company Fibrocell Science Inc plans to raise $23m in a public offering of shares of its common stock.

Underwriters have a 30-day option to purchase additional shares to cover over-allotments if any.

Sensus Healthcare Inc plans to raise $20m through a public offering of shares of its common stock, preferred stock, warrants, stock purchase contracts and other securities.

"Underwriters have a 30-day option to purchase additional shares to cover over-allotments if any."

The US-based medical technology company proposes to use the funds for general corporate purposes including the repurchase of common stock and financing of possible acquisitions.

Voyager Therapeutics Inc plans to issue four million shares priced at $12 a share to raise $62.1m.

The US-based clinical-stage company plans to use the funds for pre-clinical and clinical development activities and other general corporate purposes.

Swiss oncology company Nouscom AG has raised €42m ($48.79m) in a series B funding round led by Abingworth LLP.

The company plans to use the funds to advance the development of its cancer vaccine NOUS-209.